𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

⭐️What to look 👀 for in your urine for cancer? Honored to film this public announcement for cancer awareness @BladderCancerUS @WorldBladderCan @IBCG_BladderCA @AmericanCancer #PatientCare #Healthcare #CancerAwareness #KnowledgeCanDiminishFear

✨EXCLUSIVE PREVIEW📷: Ahead of #ASCO26, we spoke with GU cancer experts to gain their insights into which data they're most looking forward to seeing shared at the meeting. This preview features commentary from: - @CParkMD of @Norton_Health -@sonpavde of @AdventHealthMD - @bergsa83 of @DanaFarber -@sagarapatel of @WinshipAtEmory 🔐Sign up to read their insights! @ASCO onclive.com/view/gu-cancer…

@urotoday @EAntonarakis @neerajaiims @PCFnews @CParkMD

Sign up to read our exclusive preview of the 2026 AUA Annual Meeting! This piece features insights from: ⭐@CParkMD of Norton Cancer Institute ⭐@bergsa83 of @DanaFarber_GU ⭐@shilpaonc of @ClevelandClinic Read more here: onclive.com/view/io-in-nmi… #oncology #GUcancer #pcsm #AUA2026

Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/showPdf…

👉They say the Grand Canyon is one of the 7 wonders of the world. But standing here, I’m looking at the person who built my entire world. 🚁🌵 Crossing "Grand Canyon" off my mom’s bucket list is a small way to say THANK YOU for the massive lessons she’s instilled in me. She taught me: ✅Discipline to keep going. ✅Resilience to bounce back. ✅Humility to stay grounded. ✅Empathy to see and feel others. But above all, she taught me that true success isn't defined by a title or a destination—it’s defined by how you treat everyone with kindness and humanity. ❤️ The values that create truly impactful people are almost always first taught by a mother. Happy Mother’s Day to all of the mothers making the world a better place, one lesson at a time. 🌷 #MothersDay #BucketList #GrandCanyon #Leadership #Mentorship #Values #ProfessionalDevelopment #Gratitude #Inspiration #Humanity

⚡️ Phase II data suggest that adding pembrolizumab to trimodal therapy may be a feasible bladder-preserving strategy for selected patients with MIBC. At 2 years: • Bladder-intact DFS: 60% • Metastasis-free survival: 81% • Overall survival: 83% Further phase III validation will be key. #BladderCancer #Immunotherapy @ASCOPost @EUplatinum ascopost.com/news/april-202…

HIF-2 targeting is transforming kidney cancer care. 🎙️ Chandler Park, MD, MSc, FACP and Kathryn E. Beckermann, MD, PhD break down the latest data shaping the RCC landscape. Listen now 👇 🔗 hubs.li/Q04flmKS0 @CParkMD @UofL #KidneyCancer #RCC #Oncology #OncologyUnplugged

📊 Locally Advanced Rectal Cancer (LARC) Management – High-Yield Infographic! My latest comprehensive visual guide covering: ✅ Definition, high-risk features & MRI-based risk stratification ✅ Total Neoadjuvant Therapy (TNT) as the new standard (consolidation preferred) ✅ Key trials (RAPIDO, PRODIGE 23, OPRA) + Short vs Long-course RT ✅ Surgery (TME), organ preservation (Watch & Wait for cCR) ✅ Selective adjuvant therapy & practice-changing immunotherapy in MSI-H/dMMR (Dostarlimab) ✅ Practical final algorithm (exam-ready & clinic-friendly!) Fully aligned with NCCN/ESMO guidelines – designed for quick reference by fellows, residents & practicing oncologists. Save it 📌 Share it with your team & trainees 👇 What’s your go-to TNT strategy in LARC? Feedback & discussions welcome! #LARC #RectalCancer #ColorectalCancer #Oncology #TNT #WatchAndWait #MedEd #OncoTwitter #MedTwitter

PSA nadir at 24 weeks remains one of the strongest prognostic signals mHSPC, but the meaning depends entirely on metastatic volume. ➡️ Pooled analysis of 5 STAMPEDE phase 3 trials (n=7,129) ➡️ With abi±enza + PSA ≤0.2 ng/mL at 24 wks: 96-mo OS was 64% in low-volume mets vs 45% in high-volume ➡️ Non-metastatic, node-positive: 79% 96-mo OS Could PSA nadir + volumetric burden refine clinical-trial enrichment for treatment intensification? 🩺 bit.ly/3PgpID1 #ProstateCA #mHSPC #GUonc

Not so sure that HER2 mutation should be called EGFR's poor sister any more. This poor sister is going to the prom as Queen, with her dancing shoes on! 💃

Breaking the 40-year silence in Pancreatic Cancer! The #FDA just granted Expanded Access for Daraxonrasib, a first-in-class multi-selective RAS(ON) inhibitor. #PancreaticCancer #Oncology #PrecisionMedicine #MedTwitter #Daraxonrasib

📌 High-Yield Oncology Concept Every Oncologist Must Know **Histological Transformation in Cancers** – The dynamic biology that changes everything under therapy pressure. From EGFR-mutant NSCLC → SCLC to Prostate adenocarcinoma → NEPC to Richter transformation — this one infographic covers: ✅ Definition & Pathogenesis ✅ Classic Clinical Examples ✅ When to suspect (and re-biopsy!) ✅ Diagnostic approach (tissue + NGS + IHC) ✅ Management shift & poor prognosis pearls Perfect for DM/MCh/DNB viva, theory exams & day-to-day practice. “Cancer is not static — it evolves under treatment pressure.” Save it. Share it. Teach it. Next topic dropping soon: Types of Neck Dissection Dr Rupam Manna MD @DrRupamOncology #Oncology #HistologicalTransformation #NSCLC #SCLC #ProstateCancer #MedicalEducation #VivaPrep #OncoViva #CancerBiology

How to implement RLTs in therapeutic landscape of Prostate cancer? @drlouiseemmett @ProfKHerrmann @DrMHofman @stefanofanti4 @OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @OpenMedicineHQ @MedwatchKate @Ecastromarcos @ravikanesvaran @dmukherji @scserendipity1 @CParkMD @ZilliThomas @urotoday @Uroweb @CaPsurvivorship

S. Halabi, @DukeCancer PARPi combinations: benefit is not equal for all. rPFS signal is strongest in BRCA-mutated disease. @OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @OpenMedicineHQ @MedwatchKate @neerajaiims @AzadOncology @Ecastromarcos @ravikanesvaran @dmukherji @scserendipity1

Late-line advanced colorectal cancer remains a challenging setting with limited options. A new targeted therapy (antibody-drug conjugate), telisotuzumab adizutecan, targets the MET protein and shows early activity in phase I study. ORR was ~36% (tumors shrank meaningfully) in patients with high MET protein expression. For patients who have already been through multiple treatments, finding a therapy matched to their tumor biology can make a real difference. Promising early results, but we need larger studies to confirm. @JCO_ASCO *

What is the real α/β in Prostate Cancer? In this meta-analysis in the 🟢 Journal on regard BRFS : α/β = 1.5 → no correlation α/β = 3 → everything changes (R² 68%) Practical translation : we don't know the real α/β value #radonc